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Abstract: Diabetic kidney disease (DKD) has become a global health concern, with about 40% of
people living with type 1 and type 2 diabetes mellitus developing DKD. Upregulation of vascular
endothelial growth factor (VEGF) in the kidney is a significant pathology of DKD associated with
increased glomerular vascular permeability. To date, however, current anti-VEGF therapies have
demonstrated limited success in treating DKD. Recent studies have shown that artificial sweeteners
exhibit anti-VEGF potential. The aim of this study was therefore to assess the effects of aspartame, sac-
charin, and sucralose on VEGF-induced leak using an in vitro model of the glomerular endothelium.
Saccharin and sucralose but not aspartame protected against VEGF-induced permeability. Whilst
the sweeteners had no effect on traditional VEGF signalling, GC-MS analysis demonstrated that the
sweetener sucralose was not able to enter the glomerular endothelial cell to exert the protective effect.
Chemical and molecular inhibition studies demonstrated that sweetener-mediated protection of the
glomerular endothelium against VEGF is dependent on the sweet taste receptor, T1R3. These studies
demonstrate the potential for sweeteners to exert a protective effect against VEGF-induced increased
permeability to maintain a healthy endothelium and protect against vascular leak in the glomerulus
in settings of DKD.
Keywords: artificial sweeteners; diabetic kidney disease; sweet taste receptor; glomerular;
endothelium; vascular endothelial growth factor (VEGF); gas chromatograph-mass spectrometry
(GC-MS); vascular permeability
1. Introduction
The increasing incidence of diseases linked to higher consumption of sugar-sweetened
drinks has led to a shift towards a supposedly healthier option, such as low-calorie and
non-nutritive sweeteners. Amongst these sweeteners are both synthetic (artificial) and
naturally derived sweet-taste molecules, of which artificial sweeteners are more commonly
found in both low-calorie and sugar-free foods and drinks [1]. The most commonly used,
commercially available artificial sweeteners are acesulfame–K (Sunnett®, New York, NY,
USA), aspartame (NutraSweet®, Augusta, GA, USA), saccharin (Sweet’N Low®, New York,
NY, USA), and sucralose (Splenda®, Carmel, CA, USA) [2]. These sweeteners vary in their
structure, intensity of sweetness, after-taste, and pharmacokinetics [1]. Artificial sweeteners
elicit a distinctive perceived quality—termed “sweetness”—in humans through binding to
the sweet taste receptor [3]. In humans, the sweet taste receptor belongs to the T1R class
C of G protein-coupled receptors (GPCRs). The T1R has two subtypes: the T1R member
2 and 3 (T1R2 and T1R3), which form a heterodimer to act as a sweet taste receptor [4].
Whilst the T1R2/T1R3 is a heterodimer, the T1R3 subunit can also act as a homodimer to
form a sweet taste sensor [3,5]. Indeed, the T1R3 subunit alone has been shown to play
a vital role in sweet taste sensing in the vasculature [6–8]. The sweet taste receptor acts
through the traditional GPCR-signalling pathway to activate the βγ G-protein subunits and
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phospholipase C-β (PLC-β) to stimulate cAMP production, triggering intracellular calcium
release and resulting in sweet taste perception in the sweet taste buds in the mouth [9–11].
Of significance, the sweet taste receptor has been identified in a range of extraoral locations
including the small intestine, heart, bladder, and bone [6,12–14]. Recently, the sweet taste
receptor has also been identified in the vasculature of the lungs and retina, where it plays
a key role in regulating endothelial barrier function and attenuating aberrant angiogenic
processes [7,8]. These findings raise the question of whether the expression of sweet taste
receptors occurs in other vascular beds and their potential impact on mechanisms related
to vascular disruption.
Diabetic kidney disease (DKD) is a form of microvascular complication and the major
cause of end-stage renal disease in patients with diabetes [15–17]. The growing number of
people with diabetes has a direct impact on DKD incidence, with approximately 30% and
40% of individuals with type 1 (T1DM) and type 2 (T2DM) diabetes mellitus respectively
developing DKD over a median of 15 years from the time of disease diagnosis [18–21].
DKD is a progressive condition that begins with the thickening of the glomerular basement
membrane, associated with loss of endothelial fenestrations and podocytes, followed by de-
velopment of microaneurysms, leading to exudative lesions from subendothelial deposits
of plasma proteins [22–26]. In later stages of DKD, interstitial changes and glomerulopathy
can result in segmental and global sclerosis, associated with albuminuria [17]. Studies
have shown that in DKD patients and rodent models of the disease, an increase in vascular
endothelial growth factor (VEGF) has been associated with increased vascular permeability
linked to hyperfiltration and albuminuria [27–30]. Given the pivotal role of glomerular
vascular permeability in regulating DKD pathology, therapies for the disease have been
focused on anti-VEGF approaches to attenuate this leak. Whilst effective in rodent mod-
els, a subset of diabetic patients treated with anti-VEGFs, such as Bevacizumab, display
worsening of renal injury and excessive albuminuria [31,32]. There is, therefore, a need
to develop vascular-specific therapeutics to reduce vascular permeability and therefore
albuminuria in patients living with DKD without further exacerbating the disease.
In the present study, our central hypothesis was that artificial sweeteners can protect
the glomerular endothelium against VEGF-induced permeability. We proposed that this
protective effect could be mediated by the sweet taste receptor, T1R3. We further sought to
establish the molecular mechanism through which artificial sweeteners exert this protective
effect, with a focus on cAMP-dependent signalling and oxidative stress in the endothe-
lium. This study aimed to expand our understanding of the effect of sweeteners on the
vasculature and potentially identify a new therapeutic option in the treatment of vascular
disruption in DKD.
2. Materials and Methods
2.1. Cell Line and Reagents
Primary glomerular microvascular endothelial cells (GMVEC), purchased from Cell
Systems (Kirkland, WA, USA), were cultured in complete classic medium (#4Z0-500) sup-
plemented with culture boost. The passage number was used between 3 to 7. This primary
cell line was utilised as any other relevant cell lines are immortalised rather than human
primary cells and were therefore not appropriate. Endothelial growth factor (VEGF-A165)
was purchased from Thermo-Fisher (Paisley, UK). Pure and analytical grade artificial
sweeteners, aspartame, saccharin, and sucralose, the CCK-8 cell viability kit, FITC-dextran,
N-Methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA), methanol, and ethyl acetate were
purchased from Sigma-Aldrich (Dorset, UK). Lactisole, a sweet taste inhibitor, was pur-
chased from Cayman Chemical (Ann Arbor, MI, USA). The cAMP-Screen Direct System kit
and GSH Bioxytech activity kit were purchased from Applied Biosystems and Merck Milli-
pore respectively. DharmaFECT™ reagent and siRNA (T1R3 and non-specific, scrambled)
were purchased from Dharmacon (Cambridge, UK). Anti VE-cadherin and fluorescent
secondary antibodies, deuterated sucralose, and sucralose-D6 (SC-220145) were purchased
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from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 2,7-dichlorodihydrofluorescein
diacetate (DCFDA) was purchased from Abcam (Cambridge, UK).
2.2. Cell Viability Assay
The effect of the artificial sweeteners on GMVEC viability was determined using the
cell-counting kit-8 (CCK-8), following manufacturer’s guidelines. GMVEC were exposed
to increasing concentrations (0.1–100 µM) of aspartame, saccharin, and sucralose separately
and incubated for 24 h. A vehicle control of H2O was used for 0 µM. Absorbance was
measured at 450 nm using a multi-mode microplate reader (Tecan Sunrise), and viability
was calculated as % normalised to vehicle.
2.3. Endothelial Monolayer Permeability
Changes in endothelial monolayer permeability were assessed using FITC conjugated
to 20 kDa dextran (FITC-D20). GMVEC were plated in a 24-well transwell plate (20,000 cells
per well) and incubated for 24 h, followed by treatment with the named artificial sweeteners
for 20 h at concentrations ranging from 0.1–100 µM or vehicle H2O control (0 µM). Cells
were then exposed to VEGF (50 ng/mL) for a further 4 h. FITC-D20 was added to media in
the upper chamber of the transwell filter at a concentration of 5 mg/mL and incubated for
180 s at 37 ◦C. Media from the lower and upper chamber (100 µL each) were then collected
and analysed at excitation and emission wavelengths of 485 nm to 535 nm at 1 s exposure
time using a fluorescent plate reader (Victor, Perkin Elmer). Permeability was calculated
by fluorescence accumulated in the lower chamber divided by fluorescence remaining in
the upper chamber. To validate the effect of VEGF on endothelial monolayer integrity,
an EVOM2 meter (World Precision Instruments) was used to assess the trans-endothelial
electric resistance (TEER) of the GMVEC monolayer in the presence and absence of VEGF
(50 ng/mL) [8]. Experiments were repeated following siRNA knockdown of T1R3 using
SMARTpool siGENOME siRNA duplexes (300 nM) or scrambled control duplexes with
DharmafectTM reagent 4, as previously described [7,8].
2.4. ELISA Studies for VE-Cadherin and cAMP
For the investigation of VE-cadherin expression, following culture of GMVEC, the
cells were exposed to aspartame, saccharin, or sucralose for 20 h at concentrations of
100 µM or vehicle H2O control (0 µM). Cells were then exposed to VEGF for a further 4 h.
Following treatment, GMVEC were rinsed once with Dulbecco’s phosphate-buffered saline
(DPBS) and fixed using 4% paraformaldehyde at room temperature for 10 min. An indirect
whole cell ELISA was performed as previously described [7,8], using primary antibodies
specific to the extracellular domain of VE-cadherin and fluorescent-conjugated secondary
antibodies. Measurements at excitation and emission wavelengths of 495 nm to 520 nm
were taken at 1 s exposure time using a florescent plate reader. Experiments were repeated
following siRNA knockdown of T1R3 using SMARTpool siGENOME siRNA duplexes
(300 nM) or scrambled control duplexes with DharmafectTM reagent 4, as previously
described [7,8].
To assess the impact of sweeteners on the level of intracellular cyclic adenosine
monophosphate (cAMP) in GMVEC, studies were performed following manufacturer’s
guidelines for the cAMP-Screen Direct System. Cells were exposed to VEGF (50 ng/mL) or
Forskolin (FSK), a broad activator of cAMP (10 µM), for 5, 15, and 30 min. Alternatively,
GMVEC were exposed to aspartame (10 µM), sucralose (0.1 µM), and saccharin (0.1 µM)
for 20 h followed by VEGF (50 ng/mL) exposure for a further 4 h followed by cAMP
determination. Measurements were taken at 1 s exposure time (535/590 nm) using a
florescent plate reader.
2.5. Oxidative Stress Studies
To determine the protective effect of artificial sweeteners on the oxidative state of
GMVEC, a known fluorogenic probe for the measurement of intracellular reactive oxygen
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species (ROS), 2,7-dichlorodihydrofluorescein diacetate (DCFDA), was utilised. For cellular
glutathione (GSH) measurements, the GSH Bioxytech activity kit was used. GMVEC
were seeded on black-walled, clear-bottomed, 96-well plates that had been pre-rinsed
with an attachment factor and then incubated for 24 h. Following incubation, GMVEC
were exposed to VEGF (50 ng/mL) or H2O2 (10 µM) for 4 h in the presence or absence of
N-acetyl-cysteine (NAC). Either VEGF and NAC or H2O2 and NAC were added to cells at
the same time. Alternatively, cells were exposed to aspartame (10 µM), saccharin (0.1 µM),
or sucralose (0.1 µM) for 20 h followed by further 4 h exposure to VEGF (50 ng/mL).
Irrespective of treatment, for ROS studies, DCFDA (10 µM) was then added to wells, and
the level of ROS was measured on a fluorescent plate reader for 1 s at an excitation/emission
of 485/535 nm. For GSH studies, levels of reduced or oxidised glutathione were measured
on a fluorescent plate reader for 1 s at an excitation/emission of 380/461 nm. GSH levels
were expressed as normalised to vehicle (H2O) treatment.
2.6. Gas Chromatography–Mass Spectrometry
Gas Chromatography–Mass Spectrometry (GC–MS) analysis was adapted from Qiu
et al. [33], using a Perkin Elmer Clarus 500 GC-MS equipped with an electron-impact ion
source with an electron energy of 70 eV. The GC capillary column was an Rtx-5ms with
a 30-m length, 0.25-mm internal diameter, and 0.25-µm thickness. The carrier gas was
helium (BOC, 99.95%) at a flow rate of 0.6 mL/min. The instrumental parameters and
method set-up were as follows: injection port temperature (270 ◦C); injection volume (1 µL);
oven temperature parameters (180 ◦C for 2 min, 6 ◦C/min until 250 ◦C, hold for 20 min);
transfer line temperature (280 ◦C); solvent delay time (3.5 min); injection mode (Split 9:1);
and Scan 40–600 m/z. To optimise and validate the GC–MS method, selection of internal
standard (sucralose-d6), linearity, limit of detection and quantification (LOD and LOQ),
and precision were assessed following ICH guidelines [34]. This method was then applied
to the cell studies.
Sucralose (5 mg) powder was dissolved in 10 mL of methanol to make a 0.5-mg/mL
(500 µg/mL) stock solution. The stock solution of sucralose was then diluted down
with methanol to get the desired concentrations. To optimise the derivatising reaction
of sucralose with MFSTA, preliminary studies included different reaction times (30, 45,
60 min) and temperature (room temperature and 70 ◦C). Based on the findings, the reaction
temperature for 70 ◦C for 30 min was selected. Equal volumes (100 µL) of sucralose
(100 µg/mL) and sucralose d6 (50 µg/mL) were aliquoted into a glass vial, and the solvent
was evaporated using a miVac sample concentrator. Once the solvent was evaporated,
100 µL of MSTFA was added, and the mixture was heated at 70 ◦C for 30 min to derivatise.
The derivatisation of sucralose using MSTFA led to the generation of sucralose-TMS, which
was then injected into the GC–MS for analysis. To determine the suitability and stability of
the internal standard, 50 µg/mL of sucralose-d6 was derivatised and analysed for 72 h. The
analyte of interest, sucralose, in the presence of the internal standard, was analysed over
24 h for intraday precision and over 3 days to assess inter-day precision. Finally, calibration
standards between 4–400 µg/mL were analysed and their LOD and LOQ calculated.
2.7. Preparation of GMVEC for GC–MS Analysis
To determine the presence of sucralose in GMVEC, cultured cells were exposed to 4, 40,
100, 200 and 400 µg/mL sucralose concentrations for 24 h. GMVEC extraction was adapted
from Gunduz et al. [35], excluding the derivatisation reaction. Following treatment with
sucralose, used media was aspirated off, and cells were washed 6 times with phosphate-
buffered saline (PBS). The GMVEC were then soaked in methanol and scraped. The cell
suspension was transferred into tubes, sonicated, vortexed, and centrifuged at 1000 rpm
for 10 min. The supernatant of the cell lysate was transferred into glass vials, mixed with
100 µL of internal standard, and dried. Derivatisation of the cell sample mix was done
using 100 µL of MSTFA at 70 ◦C for 30 min and analysed utilising the GC–MS protocol for
sucralose as outlined above. To determine whether the sucralose remained in the cell media
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after 24 h of post-sucralose treatment, the media from each well was removed and pipetted
into glass vials. A total of 100 µL of the used media was mixed with 100 µL (50 µg/mL)
of internal standard and dried and derivatised with 100 µL of MSTFA at 70 ◦C for 30 min,
followed by GC–MS analysis.
2.8. Statistical Analysis
All data sets were statistically analysed using GraphPad Prism version 8.2.0 for
Windows (San Diego, CA, USA). Statistical analysis was performed using a one-way or
two-way ANOVA with Tukey multiple comparisons post-hoc test where relevant. The
experimental number is stated in the figure legend for each graph in the results section. The
data is presented as mean ± standard error mean (S.E.M.) except where stated otherwise,
with significance reached when p < 0.05.
3. Results
3.1. Artificial Sweeteners Saccharin and Sucralose Attenuate VEGF-Induced Permeability in
Glomerular Microvascular Endothelium
The concentration of artificial sweeteners found in various foods and drinks differs
according to each product consumed. However, there are specified acceptable daily in-
takes of these sweeteners: aspartame (40 mg/kg); saccharin (5 mg/kg); and sucralose
(15 mg/kg) [2,36]. Bioavailability studies indicate concentration ranges of between 2–15%
of the ingested dose in circulation, as the artificial sweeteners with the exception of aspar-
tame are poorly absorbed [37–39]. Based on this evidence, a range of physiologically
relevant concentrations of 0.1–100 µM were first assessed for any cytotoxic effect on
GMVEC in vitro. The results showed that the artificial sweeteners, aspartame, saccha-
rin, and sucralose, had no impact on GMVEC viability at concentrations of up to 100 µM
(Figure 1a).
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Figure 1. Artificial sweeteners, saccharin and sucralose, attenuate VEGF-induced leak across the glomerular microvas-
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The protective effect of aspartame, saccharin, and sucralose in maintaining the glomeru-
lar endothelial barrier was then investigated. VEGF was used to induce a significant increase
in GMVEC monolayer permeability, as measured by FITC-dextran assay (Figure 1(bi)) and
trans-endothelial electrical resistance (TEER-Figure 1(bii)). To assess the protective effect
of sweeteners in settings of VEGF-induced leak, GMVEC were treated with sweeteners
at varying doses, from 0.1–100 µM, in the presence and absence of VEGF. In the absence
of VEGF, aspartame, saccharin, and sucralose exerted no effect on glomerular microvas-
cular monolayer permeability (Figure 1c–e). Aspartame demonstrated a dose-selective
effect, with protection against VEGF-induced permeability only observed at higher con-
centrations of 10 and 100 µM (Figure 1c). In contrast, saccharin and sucralose abolished
VEGF-mediated monolayer leak at all the studied concentrations (Figure 1d,e).
To further establish this protective effect of sweeteners on the glomerular endothelial
barrier, the surface-level expression of the adherens junction protein, VE-cadherin, was in-
vestigated using the lowest barrier-protective concentration of each sweetener (aspartame—
10 µM; saccharin and sucralose—0.1 µM). In the absence of VEGF, aspartame, saccharin,
and sucralose maintained consistent surface-level expression of VE-cadherin in GMVEC
(Figure 1f). Following exposure to VEGF, the sweeteners maintained high surface expres-
sion level of VE-cadherin at the cell surface, indicating a protected monolayer (Figure 1f).
These findings demonstrate that the artificial sweeteners, aspartame, saccharin, and su-
cralose, are non-toxic to the endothelium and also attenuate VEGF-induced leak across the
in vitro model of the glomerular microvasculature.
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the sweet taste receptor, lactisole, was used [5,40]. Lactisole blocked the protective effect of
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3.3. Artificial Swee eners Do Not Impact cAMP or Oxid tive Stress Pathways in the
Glomerular Microvasculature
Our next exper ments sough to d termine the po ential mechanism through which
aspartame, saccharin, and sucralose protect the glomerular microvasculature against VEGF-
induced leak. Th most well-studied downstream signal of T1R2/T1R3 activation is the
release of intracellular cyclic adenosine monophosphate (cAMP), a modulator of endothe-
lial barrier function through reorganisation of the actin molecules and adherens junctional
proteins associated with cell–cell adhesion [35,41]. Therefore, we next evaluated the effect
of each artificial sweetener on intracellular cAMP levels in the glomerular microvascula-
ture. We first established the cAMP assay using Forskolin, which activates adenyl cyclase
(Figure 3a), and VEGF as our model of vascular injury (Figure 3b). Both increased intracel-
lular cAMP levels significantly from 5–15 min in a time-dependent manner. Interestingly,
in the presence and absence of VEGF, the artificial sweeteners, aspartame, sucralose, and
saccharin, had no effect on intracellular cAMP levels in GMVEC (Figure 3c).
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Table 1. Molecular inhibition of T1R3 with siRNA has no impact on sweetener-induced protection against VEGF-induced
barrier leak across the glomerular microvascular endothelial cell. GMVEC were transiently transfected with T1R3 siRNA or
non-specific scrambled control siRNA (300 nM) for 24 h followed by exposure to artificial sweeteners aspartame (10 µM),
saccharin (0.1 µM), and sucralose (0.1 µM) for 20 h. Cells were then exposed to VEGF (50 ng/mL) for a further 4 h.
Permeability was assessed using FITC-dextran assay (panel a), and VE-cadherin cell-surface expression was measured





Treatment: Vehicle Aspartame Saccharin Sucralose Vehicle Aspartame Saccharin Sucralose
Vehicle 1.77 ± 0.25 1.99 ± 0.57 1.88 ± 0.73 1.71 ± 0.58 1.95 ± 0.38 2.06 ± 0.61 1.89 ± 0.67 1.59 ± 0.73
VEGF 5.91 ± 0.62 * 2.05 ± 0.41 2.01 ± 0.60 1.89 ± 0.36 5.79 ± 0.55 * 1.83 ± 0.71 2.13 ± 0.82 1.98 ± 0.40
(b)
siRNA
VE-Cadherin Cell-Surface Expression (r.f.u.)
Scrambled T1R3
Treatment: Vehicle Aspartame Saccharin Sucralose Vehicle Aspartame Saccharin Sucralose
Vehicle 4038 ± 693 4126 ± 827 4150 ± 1017 4061 ± 904 4183 ± 1027 5199 ± 757 4289 ± 863 4890 ± 1007
VEGF 971 ± 183 * 4090 ± 938 4281 ± 1105 4135 ± 1036 891 ± 130 * 4937 ± 812 3980 ± 1170 4136 ± 1021
Nutrients 2021, 13, x FOR PEER REVIEW 8 of 16 
 
 
Table 1. Molecular inhibition of T1R3 with siRNA has no impact on sweetener-induced protection against VEGF-induced 
arrier leak across t e gl merular microvascular endothelial cell. GMVEC were transiently tra sfected with T1R3 siRNA 
o  non-spe ific scrambled control siRNA (300 M) for 24 h followed by xposure to artificial sweeteners aspartame (10 
µM), saccharin (0.1 µM), and sucralose (0.1 µM) for 20 h. Cells were then exposed to VEGF (50 ng/mL) for a further 4 h. 
Permeability was assessed using FITC-dextran assay (panel a), and VE-cadherin cell-surface expression was measured 
using the whole-cell ELISA (panel b). n = 5–6. Data are expressed as mean with S.E.M * p < 0.05 vs. vehicle for VEGF. 
(a) 
siRNA 
Permeability Ratio (Base/Insert) 
Scrambled T1R3 
Treatment: Vehicle Aspartame Saccharin Sucralose Vehicle Aspartame Saccharin Sucralose 
Vehicle 1.77 ± 0.25 1.99 ± 0.57 1.88 ± 0.73 1.71 ± 0.58 1.95 ± 0.38 2.06 ± 0.61 1.89 ± 0.67 1.59 ± 0.73 
VEGF  5.91 ± 0.62 * 2.05 ± 0.41 2.01 ± 0.60 1.89 ± 0.36 5.79 ± 0.55 * 1.83 ± 0.71 2.13 ± 0.82 1.98 ± 0.40 
(b) 
siRNA 
VE-Cadherin Cell-Surface Expression (r.f.u.) 
Scrambled T1R3 
Treatment: Vehicle Aspart e Saccharin Sucralose Vehicle Aspartame Saccharin Sucralose 
Vehicle 4038 ± 693 4126 ± 827 4150 ± 1017 4061 ± 904 4183 ± 1027 5199 ± 757 4289 ± 863 4890 ± 1007 
VEGF 971 ± 183 * 4090 ± 938 4281 ± 1105  4135 ± 1036 891 ± 130 * 4937 ± 812 3980 ± 1170 4136 ± 1021 
 
 
Figure 3. Artificial sweetener regulation of the glomerular endothelium is independent of cAMP and intracellular ROS 
generation. Panel (a–c): generation of intracellular cAMP upon exposure of GMVEC to aspartame (10 µM), saccharin (0.1 
µM), and sucralose (0.1 µM) for 24 h in the presence and absence of VEGF (panel b) using the cAMP-Screen Direct chem-
iluminescent ELISA assay. Forskolin (FSK), 10 µM, was used to validate the assay (panel a). Panel (d–f): GMVEC were 
treated with VEGF or H2O2 (10 µM) or vehicle (H2O) in the presence or absence of NAC (10 µM), followed by incubation 
with DCFDA (10 µM) and fluorescence analysis (panel d). These experiments were repeated following pre-exposure to 
aspartame (10 µM), saccharin (0.1 µM), and sucralose (0.1 µM) for 2 h in the presence and absence of VEGF (panel e). ROS 
production was assessed by measuring the florescence level of DCF following staining with 10 µM DCFDA. For cellular 
glutathione (GSH) measurements (panel f), GMVEC were pre-exposed to aspartame (10 µM), saccharin (0.1 µM), and 
sucralose (0.1 µM) in the presence and absence of VEGF. Data are expressed as mean with S.E.M and n = 6. * p <0.05 vs. 
vehicle for sweetener; δ p < 0.05 vs. vehicle for VEGF or H2O2. 
We next studied the effect of the artificial sweeteners, aspartame, saccharin, and su-
cralose, on the endothelial stress signal, reactive oxygen species (ROS). Intracellular accu-
mulation of ROS is linked to tyrosine phosphorylation of VE-cadherin and the subsequent 
Figure 3. Artificial sweetener regulation of the glomerular endothelium is independent of cAMP and intracellular ROS
generation. Panel (a–c): generati f i tr cell l r c upon exposure of GMVEC to aspartame (10 µM), saccharin
(0.1 µM), and sucralose (0.1 µM) for 24 h in the pres nce and abs nce of VEGF (panel b) using the cAMP-Screen Direct
chemilumin scent ELISA assay. Forskolin (FSK), 10 µM, was used to li t t ssay (panel a). Panel (d–f): GMVEC wer
treated with VEGF or H2O2 (10 µM) or vehicle (H2O) in the presence or absence of NAC (10 µM), followed by incubation
with DCFDA (10 µM) and fluorescence analysis (panel d). These experiments were repeated following pre-exposure to
aspartame (10 µM), saccharin (0.1 µM), and sucralose (0.1 µM) for 2 h in the presence and absence of VEGF (panel e). ROS
production was assessed by measuring the florescence level of DCF following staining with 10 µM DCFDA. For cellular
glutathione (GSH) measurements (panel f), GMVEC were pre-exposed to aspartame (10 µM), saccharin (0.1 µM), and
sucralose (0.1 µM) in the presence and absence of VEGF. Data are expressed as mean with S.E.M and n = 6. * p <0.05 vs.
vehicle for sweetener; δ p < 0.05 vs. vehicle for VEGF or H2O2.
We next studied the effect of the artificial sweeteners, aspartame, saccharin, and
sucralose, on the endothelial stress signal, reactive oxygen species (ROS). Intracellular accu-
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mulation of ROS is linked to tyrosine phosphorylation of VE-cadherin and the subsequent
loss of cell–cell adhesion, resulting in vascular leak [42,43]. We utilised an established
probe for the measurement of intracellular ROS, 2,7-dichlorodihydrofluorescein diacetate
(DCFDA), and demonstrated the probe sensitivity using hydrogen peroxide (H2O2) to
induce ROS and the antioxidant N-acetyl cysteine (NAC) to decrease ROS (Figure 3d). In
the absence of VEGF, aspartame significantly increased ROS accumulation in GMVEC,
whilst saccharin and sucralose had no effect (Figure 3e). In the presence of VEGF, there
was a significant increase in ROS accumulation, which was unaffected by exposure to
saccharin, sucralose, and aspartame (Figure 3e). This finding was mirrored in studies
assessing cellular glutathione (GSH) levels in GMVEC, with VEGF significantly lowering
GSH expression and sweeteners having no impact on the oxidative process (Figure 3f).
Taken together, these findings demonstrate that artificial sweeteners, aspartame, sac-
charin, and sucralose, act through a non-traditional signalling pathway in the glomerular
microvasculature.
3.4. Analysis and Detection of Sucralose by GC–MS
To further understand how sweeteners impact the endothelium and given that T1R2/T1R3
endocytosis has been previously demonstrated [44], we next evaluated the trafficking of
artificial sweeteners into the endothelial cell. To address this, we utilised an analytical tech-
nique, GC–MS, and focused on the sweetener that has been studied using this technique,
sucralose [45]. Polar compounds, such as sucralose, require chemical modification, known
as derivatisation, prior to analysis by GC-MS [45]. Following derivatisation of sucralose
with MSTFA, the hydroxyl functional groups of sucralose were replaced with a trimethyl
silyl group. Derivatised sucralose (sucralose-TMS) was detected with a peak at 22.29 min
retention time and the internal standard (sucralose-d6) at 22.14 min (Figure 4). The identifi-
cation of the peak as sucralose-TMS was further confirmed through the examination of its
mass spectra. The main ions of interest of sucralose were at mass/charge (m/z) 207, 308,
and 343 (Figure 5b) [33], differentiating it from those of the internal standard (Figure 5a),
whose main ions were at m/z 211, 312, and 347.
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the internal standard, sucralose-d6 (panel a), and sucralose-TMS (panel b). The base ions of both mass spectra (circled red) 
are m/z 312 for internal standard and m/z 308 for sucralose-TMS. The qualifier ions (circled green) are m/z 347 for the 
internal standard and m/z 343 for sucralose-TMS following GC–MS analysis. 
Prior to its application to cell studies, the GC–MS method was optimised and vali-
dated. The suitability of internal standards, precision, linearity, limit of detection (LOD), 
and limit of quantification (LOQ) were assessed [46]. The stability of the sucralose-d6 over 
72 h (Figure 6a) demonstrated its suitability as an internal standard (RSD < 5%). Due to 
co-elution of the internal standard, an extracted ion chromatogram (sucralose: m/z 308; 
sucralose-d6: m/z 312) was used for data analysis. Our results from inter- and intra-day 
precision studies further show (Figure 6b,c) an RSD below 5%, meeting the Scientific 
Working Group for Forensic Toxicology (SWGTOX) and other international guidelines 
[46,47]. The regression plot of sucralose was linear from 4–400 µg/mL (r2 = 1.000), and 
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3.5. The Artificial Sweetener Sucralose Does Not Enter the Glomerular Endothelium
Finally, we sought to determine whether sucralose is transported into and across the
glomerular microvascular endothelium as a potential mechanism of attenuating VEGF-
induced permeability. Following the optimisation and validation of the developed method
for GC–MS detection of sucralose (Figures 4 and 5), the same technique was applied to cell
lysates. Our results indicated that no sucralose was detected in the cytosol of glomerular
microvascular endothelial cells but rather remained in the extracellular space (cell media)
(Figure 6d,e). These results, therefore, suggests that the artificial sweetener, sucralose, is not
endocytosed nor diffuses into the glomerular microvascular endothelial cell and therefore
is likely to protect against VEGF-induced permeability through an alternative mechanism.




Figure 6. Sucralose was not taken into glomerular endothelial cells. Instrument auto-sampler stability was evaluated as 
part of the method validation prior cell analysis. Panel (a): bar graph of peak area of internal standard (50 µg/mL) plotted 
against various injection times to determine the autosampler stability of the instrument (GC–MS) and suitability of the 
internal standard. There was no statistically significant difference between the injections and control using two-way 
ANOVA. Panel (b,c): inter and intra-day precision of sucralose-d6. The intra-day (panel b) covers data generated over 24 
h, while inter-day (panel c) covers an analysis time of 3 days. The results were analysed using two-way ANOVA and error 
bars presented as standard deviation with 36 technical repeats. The calculated RSD shown on the top of the bars shows 
RSD deviation between repeated runs. Results in panels (d) and (e) indicate that sucralose is not transported across the 
glomerular endothelial cell membrane. GMVEC were plated and incubated at 37 °C for 24 h, followed by exposure to 500 
µL sterile-filtered sucralose concentrations ranging from 4 to 400 µg/mL and then incubated for an additional 24 h. The 
cell lysate (panel d) and used media (panel e) were aliquoted into glass vials, mixed with internal standard, evaporated to 
dryness, derivatised with MSTFA at 70 °C for 30 min, and analysed using GC–MS. The instrument (GC) conditions were 
as outlined in the methods section. The mean peak area ratio of the mixed analyte was plotted against sucralose concen-
trations. n = 3 of independent experimental repeats. 
3.5. The Artificial Sweetener Sucralose Does Not Enter the Glomerular Endothelium 
Finally, we sought to determine whether sucralose is transported into and across the 
glomerular microvascular endothelium as a potential mechanism of attenuating VEGF-
induced permeability. Following the optimisation and validation of the developed 
method for GC–MS detection of sucralose (Figures 4 and 5), the same technique was ap-
plied to cell lysates. Our results indicated that no sucralose was detected in the cytosol of 
glomerular microvascular endothelial cells but rather remained in the extracellular space 
(cell media) (Figure 6d,e). These results, therefore, suggests that the artificial sweetener, 
sucralose, is not endocytosed nor diffuses into the glomerular microvascular endothelial 
cell and therefore is likely to protect against VEGF-induced permeability through an al-
ternative mechanism.  
4. Discussion 
The aim of the present study was to determine the protective effect of artificial sweet-
eners, aspartame, saccharin, and sucralose, on VEGF-induced permeability in a cell model 
of the glomerular microvascular endothelium. We demonstrated that the artificial sweet-
eners displayed differential effects on GMVEC processes. Whilst saccharin and sucralose 
protected the in-vitro glomerular microvasculature model against VEGF-induced leak at 
Figure 6. Sucralose was not taken into glomerular endothelial cells. Instrument auto-sampler stability was evaluated
as part of the method validation prior cell analysis. Panel (a): bar graph of peak area of internal standard (50 µg/mL)
plotted ag inst various i jection times to determine the autosampler stability of the instrument (GC–MS) and suitability of
the internal standard. There was no statistically sign ficant difference betw en the j i c t l using two-way
ANOVA. Panel (b,c): inter an intra- ay precision of sucralose- 6. The intra-day (panel b) covers data generated over
24 h, while inter-day (panel c) covers an analysis time of 3 days. The results were analysed using two-way ANOVA and
error bars presented as standard deviation with 36 technical repeats. The calculated RSD shown on the top of the bars
shows RSD deviation between repeated runs. Results in panels (d) and (e) indicate that sucralose is not transported across
the glomerular endothelial cell membrane. GMVEC were plated and incubated at 37 ◦C for 24 h, followed by exposure to
500 µL sterile-filtered sucralose concentrations ranging from 4 to 400 µg/mL and then incubated for an additional 24 h. The
cell lysate (panel d) and used media (panel e) were aliquoted into glass vials, mixed with internal standard, evaporated to
dryness, deriva is d with MSTFA at 70 ◦C for 30 min, and analysed using GC–MS. The instrum nt (GC) conditions were as
outlined i the methods section. Th mea peak area ratio of the mixed analyte was plotted against sucralose concentrations.
n = 3 of independent experimental repeats.
4. Discussion
The aim of the present study was to determine he protective effect of artificial sweet-
e ers, asparta , saccharin, and sucralose, on VEGF-induced permeability in a cell m d l
of the glomerular microvascular endothelium. We demonstra ed that th art ficial sweet-
eners displayed differential effects on GMVEC processes. Whil t saccharin and sucral se
protected the in-vitro glomerular microvasculature model against VEGF-induced le k at ll
studied concentrations, aspartame was only p otective at higher conc ntrations. Chemical
inhibition of T1R2/T1R3 and m lecular inhibition of T1R3 blunted this protective eff ct;
however, we demonstrated that the sweeteners did not impact cAMP levels, a traditional
downstrea signalling second messenger of T1R2/T1R3, or ROS accumulation, a typical
regulator of endothelial cell health. Lastly, we developed a novel analytical tool to study
sucralose levels and used this to demonstrate that the sweetener cannot enter the glomeru-
lar endothelial cell via T1R2/T1R3 endocytosis to exert this protective effect. Overall,
these studies indicate the potential role of sweeteners as a novel therapeutic option in
ameliorating glomerular vascular leak observed in individuals living with DKD.
In the glomerulus, VEGF released from podocytes plays a key role in promoting
endothelial fenestration integrity and regulating barrier function [48]. However, excessive
VEGF release has been associated with diabetic kidney disease [27,49]. Furthermore, VEGF
levels positively correlate with albuminuria in patients with diabetes, suggesting that the
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growth factor plays a key role in renal injury [50]. Overstimulation of the VEGF receptor 2
(VEGFR2) in a genetic mouse model results in mesangial matrix expansion, endothelial cell
proliferation, and massive proteinuria [51]. There is also an increase in capillary number
and area in the early stages of DKD, indicative of excessive angiogenesis, associated with
vascular leak and regrowth [52]. As such, anti-VEGF therapies have been studied in
animal models of both type 1 and type 2 diabetes with some success observed; for example,
decreased albuminuria and reduced glomerular hypertrophy have been observed [30,53,54].
However, in clinical studies using the humanized monoclonal antibody, bevacizumab,
proteinuria, and hypertension have been reported, linked to swelling of the glomerular
endothelial cells and thrombotic microangiopathy [55–57]. There are, therefore, potential
therapeutic applications for an anti-VEGF therapy for patients with DKD; however, there
is a need to overcome the associated side effects and worsening of renal injury.
In the present study, we investigated a novel regulator of glomerular endothelial
function, namely artificial sweeteners. We demonstrated that aspartame, saccharin, and
sucralose attenuated VEGF-induced leak; however, in the absence of VEGF, these sweet-
eners exerted no negative effect on barrier function or cytotoxicity. These studies thus
indicate that sweeteners will not impact the healthy endothelium but will protect the
leaky endothelium and therefore could offer a potential for use as a therapeutic option
for patients with DKD. However, it is worth noting that aspartame increased oxidative
stress in GMVEC in the absence of VEGF. These findings are consistent with our previous
studies, which demonstrated a barrier-protective effect of the artificial sweetener, sucralose,
in settings of VEGF-induced retinopathy and LPS-induced pulmonary edema [7,8]. Fur-
thermore, Schiano et al. identified a range of genes in endothelial cells that are affected by
sweeteners, including CDH5, NOS3, HIF1A, and PTK2 [58]. The products of these genes are
vital in reducing oxidative stress and improving barrier integrity in the microvasculature.
However, in our present study, we showed that saccharin, sucralose and aspartame have
no effect on oxidative stress in GMVEC, but they did tighten the microvascular barrier. It
is therefore likely that sweeteners protect the endothelium through a ROS-independent
mechanism. Given our findings showing that sweeteners stabilised VE-cadherin expres-
sion at the cell surface in settings of VEGF exposure, it is possible that they can directly
impact adherens junction stability to protect against VEGF-induced barrier disruption.
Interestingly, we also demonstrated that the barrier-protective effect of these sweeteners
was blocked by exposure to the T1R2/T1R3 inhibitor, lactisole, and molecular inhibition
of T1R3 had the same effect. These studies indicated that activation of T1R3 is essential
in exerting the barrier-protective effect of sweeteners. Previous studies have shown the
presence of T1R2/T1R3 in the kidney or indicate the importance of T1R3 in regulating other
vascular beds [7,8,59]; however, the present work is the first to study the role of sweeteners
and the sweet taste receptor in regulating vascular function in the glomerulus.
Whilst all three sweeteners studied were protective against VEGF-induced leak across
the glomerular endothelium, both saccharin and sucralose were protective at low concen-
trations (0.1 µM), whilst aspartame was only protective at higher concentrations (>10 µM).
This may be due to the higher binding affinity of saccharin and sucralose sweetener to the
T1R2/T1R3 complex as compared to aspartame [60] such that a higher concentration of
aspartame is needed to stimulate the sweet taste receptor and promote barrier protection
against VEGF injury. Despite this difference, it is worth noting that the concentration range
of sweeteners that was studied here, 0.1 to 100 µM, is within the normal range that can be
found in circulation [37–39]. In theory, it is therefore possible that consumption of artificial
sweeteners in the diet could improve vascular function in patients with DKD. However,
there are many studies that indicate the worsening of glucose intolerance, disruption of
gut function, and vascular reactivity following consumption of sucralose, saccharin, and
acesulfame K [14,61,62]; therefore, further study is needed to establish how to harness the
barrier-protective role of artificial sweeteners without worsening the health of patients
with diabetes.
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Following activation by a range of sweet taste molecules, including artificial sweet-
eners, the downstream signalling of T1R2/T1R3 typically involves cAMP-dependent
activation of PLC [10,63]. In the present study, we observed no effect of sweeteners on
intracellular cAMP levels in the presence or absence of VEGF. Whilst we demonstrated
the efficacy of the assay to evaluate cAMP using both Forskolin and VEGF, it is possible
that the sweeteners regulate local or compartmentalised cAMP levels, which cannot be
evaluated with this ELISA. However, it is also possible that the sweeteners do not act
through a traditional taste-signalling pathway in the glomerular endothelium. Previous
studies have indicated that desensitisation of the T1R2/T1R3 occurs through endocytosis;
however, it is not clear whether this internalisation process includes sweeteners bound
to T1R2/T1R3 [44]. Therefore, to further understand the impact of sweeteners on the
glomerular endothelium, we developed a sensitive analytical tool to detect sweeteners
in the endothelial cell, with a focus on sucralose as the more well-studied sweetener in
the microvasculature [7,8]. Our findings conclude that sucralose is not internalised into
the glomerular endothelial cell cytosol, which indicates that further study is needed to
understand the molecular mechanism through which sucralose and saccharin exert an
antioxidant and barrier-protective role on the endothelium.
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